Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 3 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Tristan Manalac, 04 Sep 2020
Anticoagulation therapy may be of value to patients with new-onset atrial fibrillation (AF) associated with sepsis, easing the risk of all-cause mortality and ischaemic stroke without increasing the likelihood of major bleeding, reports a study presented at the Digital 2020 Congress of the European Society of Cardiology (ESC).

Epeleuton flops for liver protection

07 Sep 2020

Epeleuton, a second‐generation synthetic n‐3 fatty acid derivative of eicosapentaenoic acid, falls short of improving alanine aminotransferase (ALT) or liver stiffness in patients with nonalcoholic fatty liver disease (NAFLD), according to a study. However, it has potential for cardiovascular risk reduction by simultaneously targeting hypertriglyceridemia, hyperglycaemia, and systemic inflammation.

Ninety-six adult NAFLD patients (28.1 percent had diabetes) who were overweight or obese (BMI 25–40 kg/m2) were randomized to receive epeleuton 1 g, 2 g, or placebo daily for 16 weeks. Patients in the placebo group had higher serum ALT levels (median, 70.5, 74.0, and 96.5 U/L, respectively) and liver stiffness (median, 8.16, 7.90, and 8.42 kPa), while those who in the 2-g group had higher triglycerides (median, 146.0, 242.0, and 150.0 mg/dL).

The trial did not meet its primary endpoints of improvements in ALT and liver stiffness at week 16. However, there were noticeable effects on cardiometabolic markers. Specifically, epeleuton 2 g yielded significant declines in triglycerides, very‐low‐density lipoprotein, and total cholesterol levels without increasing low‐density lipoprotein cholesterol.

Also, the higher dose produced a greater decrease in HbA1c compared with placebo (−0.4 percent vs −0.08 percent; p=0.026), despite a low mean baseline HbA1C (6.3 percent). Among patients with baseline HbA1c >6.5 percent, epeleuton 2 g reduced HbA1c by 1.1 percent (vs −0.26 percent with placebo; p=0.047).

There were consistent dose‐dependent reductions seen in fasting plasma glucose, insulin, and insulin resistance indices. Finally, epeleuton 2 g decreased circulating markers of cardiovascular risk and endothelial dysfunction.

Overall, the drug was well tolerated, with a safety profile similar to placebo.

More studies are needed to validate the findings and investigate the full therapeutic effects of epeleuton for treating NAFLD, hyperglycaemia, dyslipidaemia, as well as for preventing ischaemic events.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 3 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Tristan Manalac, 04 Sep 2020
Anticoagulation therapy may be of value to patients with new-onset atrial fibrillation (AF) associated with sepsis, easing the risk of all-cause mortality and ischaemic stroke without increasing the likelihood of major bleeding, reports a study presented at the Digital 2020 Congress of the European Society of Cardiology (ESC).